Memorabilia


Development process

development path


2022.11

Approved as Jiangsu Provincial Graduate Workstation

2022.08

Won the Nanjing Unicorn Cultivation Award

2022.05

Approved as Nanjing Engineering Technology Research Center for Differentiated Generic Drugs

2021.02

Introducing Yuanda Group’s strategic investment in health industry

2020.12

Jiangsu Province Intellectual Property Standard Implementation Unit

2020.09

Biopharmaceutical GP801 project won the Most Market Value Award

2020.06

Biological drug GP801 approved for clinical trials

2020.05

Class 2 GP501 anti-tumor drug approved for clinical use

2019.12

Won the title of R&D Enterprise in Jiangsu Province

2019.11

Anti-insomnia drug GP401 approved for clinical trials

2019.04

"Nanjing Generic Drug Quality and Efficacy Consistency Evaluation Engineering Research Center"

2018.10

Won the first batch of "Nanjing Gazelle Enterprise"

2018.06

Won the title of "Top 20 Chinese Pharmaceutical R&D Companies"

2017.12

The company's stock was successfully issued through private placement and raised 50 million yuan.

2017.11

Reached strategic cooperation with the American JVC company, introduced JVS-100 (GP801), established a subsidiary, Jiqun Biotech, and started research and development in the field of biopharmaceuticals!

2017.03

Successfully logged into the New OTC Market OC:870803

2016.11

Won the title of "National High-tech Enterprise"

2016.07

Chairman Li Zhan was selected into the "National High-Level Talent Special Support Plan" (Ten Thousand Persons Plan)

2016.06

Won the title of “Jiangsu Private Technology Enterprise”

2016.05

Introduced strategic investors and raised 21 million yuan

2016.01

Obtained the first batch of support from the Guozitou Fund-"National Small and Medium Enterprises Development Fund"

2015.12

Introduced angel investors and raised 13 million yuan

2015.09

Settled in Nanjing Life Technology Town

2015.03

Ms. Huo Liru won the title of "Nanjing Technology Entrepreneur"

2013.11.08

The birth of Jiqun Medicine